Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has entered into a Material Transfer Agreement with a pharmaceutical company, referred to as 'PharmaCo'. The agreement aims to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. Under the terms:
1. Lexaria will formulate and supply specific DehydraTECH compositions.
2. PharmaCo will conduct animal studies to evaluate the pharmacokinetics of these compositions.
3. PharmaCo has been granted a temporary exclusive license option for specific DehydraTECH concepts and formulations under examination.
The evaluation process is expected to be completed within approximately 6 months or less. This agreement represents a significant step for Lexaria in advancing its drug delivery platform technology.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ha stipulato un Accordo di Trasferimento di Materiale con una compagnia farmaceutica, chiamata 'PharmaCo'. L'accordo ha come obiettivo la valutazione della tecnologia DehydraTECH di Lexaria in un contesto pre-clinico. Secondo i termini:
1. Lexaria preparerà e fornirà specifiche composizioni DehydraTECH.
2. PharmaCo condurrà studi sugli animali per valutare la farmacocinetica di queste composizioni.
3. A PharmaCo è stata concessa un'opzione di licenza esclusiva temporanea per specifici concetti e formulazioni DehydraTECH in fase di esame.
Il processo di valutazione dovrebbe essere completato entro circa 6 mesi o meno. Questo accordo rappresenta un passo significativo per Lexaria nel progresso della sua tecnologia per la somministrazione di farmaci.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ha firmado un Acuerdo de Transferencia de Material con una empresa farmacéutica, conocida como 'PharmaCo'. El acuerdo tiene como objetivo evaluar la tecnología DehydraTECH de Lexaria en un entorno preclínico. Según los términos:
1. Lexaria formulará y proporcionará composiciones específicas de DehydraTECH.
2. PharmaCo llevará a cabo estudios en animales para evaluar la farmacocinética de estas composiciones.
3. A PharmaCo se le ha otorgado una opción de licencia exclusiva temporal para ciertos conceptos y formulaciones de DehydraTECH que se están examinando.
Se espera que el proceso de evaluación se complete en aproximadamente 6 meses o menos. Este acuerdo representa un paso importante para Lexaria en el avance de su plataforma de tecnología de entrega de medicamentos.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)는 'PharmaCo'라는 제약 회사와 물질 이전 계약을 체결했습니다. 이 계약의 목적은 Lexaria의 DehydraTECH 기술을 전임상 환경에서 평가하는 것입니다. 계약의 조건은 다음과 같습니다:
1. Lexaria는 특정 DehydraTECH 조성을 조제하고 제공합니다.
2. PharmaCo는 이러한 조성의 약동학을 평가하기 위해 동물 연구를 수행합니다.
3. PharmaCo는 검토 중인 특정 DehydraTECH 개념 및 제형에 대한 일시적인 독점 라이센스 옵션을 부여받았습니다.
평가 과정은 약 6개월 이내에 완료될 것으로 예상됩니다. 이 계약은 Lexaria가 약물 전달 플랫폼 기술을 발전시키는 데 있어 중요한 단계로 여겨집니다.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) a conclu un Accord de Transfert de Matériel avec une entreprise pharmaceutique, désignée par 'PharmaCo'. L'accord vise à évaluer la technologie DehydraTECH de Lexaria dans un cadre préclinique. Selon les termes :
1. Lexaria formulera et fournira des compositions DehydraTECH spécifiques.
2. PharmaCo effectuera des études sur les animaux pour évaluer la pharmacocinétique de ces compositions.
3. PharmaCo a obtenu une option de licence exclusive temporaire pour des concepts et formulations spécifiques de DehydraTECH en cours d'examen.
Le processus d'évaluation devrait être achevé dans environ 6 mois ou moins. Cet accord représente une étape significative pour Lexaria dans l'avancement de sa technologie de plateforme de distribution de médicaments.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) hat einen Material Transfer Agreement mit einem Pharmaunternehmen, das als 'PharmaCo' bezeichnet wird, abgeschlossen. Ziel des Agreements ist die Bewertung von Lexarias DehydraTECH-Technologie in einem präklinischen Umfeld. Die Bedingungen lauten:
1. Lexaria wird spezifische DehydraTECH-Kompositionen formulieren und bereitstellen.
2. PharmaCo wird Tierversuche durchführen, um die Pharmakokinetik dieser Kompositionen zu bewerten.
3. PharmaCo wurde eine vorübergehende Exklusivlizenzoption für spezifische DehydraTECH-Konzepte und -Formulierungen gewährt, die untersucht werden.
Der Bewertungsprozess soll innerhalb von etwa 6 Monaten oder weniger abgeschlossen sein. Dieses Agreement stellt einen bedeutenden Schritt für Lexaria dar, um ihre Arzneimittelabgabetechnologie voranzutreiben.
- Potential for expanding DehydraTECH technology applications
- Collaboration with a pharmaceutical company for pre-clinical evaluation
- Temporary exclusive license option granted, indicating industry interest
- None.
KELOWNA, BC / ACCESSWIRE / September 3, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.
Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work should be complete within roughly 6 months or less.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What is the purpose of Lexaria's Material Transfer Agreement with PharmaCo?
How long is the evaluation process expected to take for Lexaria's DehydraTECH technology?
What are Lexaria's responsibilities in the Material Transfer Agreement?
What type of license has Lexaria granted to PharmaCo in this agreement?
